Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

134
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
134
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

120
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
120
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

147
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
147
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

317
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
317
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

113
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
113
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

96
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
96

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

pH-Responsive Hydroxypropyl Cellulose-Based Membranes for Controlled Mass Transport and Drug Release.

Membranes·2026
Same author

Preliminary investigation on the seroprevalence and co-exposure of Brucella spp. and Mycobacterium avium subsp. paratuberculosis in dromedary camels from the Eastern Province of Saudi Arabia.

BMC veterinary research·2026
Same author

Biogenic <i>Caralluma sinaica</i>-derived silver nanoparticles as a synergistic antibacterial and osteoinductive nanoplatform for osteomyelitis management.

Frontiers in medicine·2026
Same author

Ajwa Date Seed-Derived Hydrogel Electrolyte with Enhanced Electrochemical Performance and Mechanical Strength for Flexible Supercapacitors.

Gels (Basel, Switzerland)·2026
Same author

Cardioprotective Role of 5,7,4'-Trimethoxy Flavanone Through PI3K/AKT-Nrf2 Signaling in Mice.

Journal of biochemical and molecular toxicology·2026
Same author

Geraniol Mitigates Cytarabine-Induced Hepatotoxicity in Mice via PI3K/AKT-Mediated NRF2 Activation.

Journal of biochemical and molecular toxicology·2026

Related Experiment Video

Updated: Jun 6, 2025

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
08:53

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Published on: July 27, 2022

805

Probiotic and Rice-Derived Compound Combination Mitigates Colitis Severity.

Ashraf Khalifa1,2, Mayyadah Abdullah Alkuwayti1, Basem M Abdallah1

  • 1Biological Science Department, College of Science, King Faisal University, P.O. Box 400, Al-Ahsa 31982, Saudi Arabia.

Pharmaceuticals (Basel, Switzerland)
|November 27, 2024
PubMed
Summary

Enterococcus lactis supplementation shows promise in managing colitis, reducing inflammation and improving gut health. Combining it with Hasawi rice protein lysate may enhance these therapeutic effects for better colitis management.

Keywords:
Al-Asfar LakeEnterococcus lactisHasawi riceinflammatory disordersprotein hydrolysate

More Related Videos

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

12.2K
Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

2.8K

Related Experiment Videos

Last Updated: Jun 6, 2025

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
08:53

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Published on: July 27, 2022

805
Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

12.2K
Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

2.8K

Area of Science:

  • Microbiology
  • Gastroenterology
  • Immunology

Background:

  • Colitis, characterized by colon inflammation, necessitates novel therapeutic strategies.
  • Dextran sulfate sodium (DSS) is a common inducer of experimental colitis in mice.
  • Exploring natural compounds and probiotics for colitis management is an active research area.

Purpose of the Study:

  • To investigate the therapeutic potential of Enterococcus lactis (E. lactis) and Hasawi rice protein lysate (HPL) in a mouse model of DSS-induced colitis.
  • To evaluate the combined effects of E. lactis and HPL on colitis parameters.
  • To assess the impact of these treatments on gut permeability, oxidative stress, and inflammatory markers.

Main Methods:

  • Male mice were induced with colitis using DSS.
  • Mice were supplemented with E. lactis and/or HPL.
  • Disease activity index (DAI), gut permeability (FITC-dextran), and colon superoxide dismutase (SOD) activity were measured.
  • Pro-inflammatory markers and levels of proteins associated with cell death were analyzed.

Main Results:

  • E. lactis supplementation significantly improved DAI scores and gut permeability in DSS-induced colitis.
  • The combination of E. lactis and HPL demonstrated superior efficacy compared to E. lactis alone.
  • Both treatments increased SOD activity, indicating reduced oxidative stress.
  • Pro-inflammatory markers and proteins linked to cell death (PCNA, PTEN, VEGF, COX-2, STAT-3) were significantly reduced.

Conclusions:

  • Enterococcus lactis shows significant therapeutic benefits for colitis.
  • Hasawi rice protein lysate may enhance the effectiveness of E. lactis for colitis treatment.
  • The combination therapy warrants further investigation for clinical application in managing inflammatory bowel diseases.